Anticoagulation for continuous renal replacement therapy

Contributions to Nephrology

Volumn 144, Issue , 2004, Pages 228-238

  Davenport, Andrew ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; THROMBIN;

DRUG ANTAGONISM; EQUIPMENT DESIGN; EXTRACORPOREAL CIRCULATION; HUMAN; INSTRUMENTATION; RENAL REPLACEMENT THERAPY; REVIEW;

ANTICOAGULANTS; EQUIPMENT DESIGN; EXTRACORPOREAL CIRCULATION; HUMANS; RENAL REPLACEMENT THERAPY; THROMBIN;

EID: 3343021090     PISSN: 03025144     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000078891     Document Type: Article

References (35)

1. Ronco C, Bellomo R, Hamel P, Brendolan A, Dan M, Piccinni P, La Greca G: Effects of different doses in continuous veno-venous hemofiltration on outcomes of acute renal failure. Lancet 2000;356:26-30.
2. Mehta RL, McDonald B, Gabbai FB, Aphl M, Pascual MTA, Karkas A, Kaplan RM: A randomised controlled trial of continuous versus intermittent dialysis for acute renal failure. Kid Int 2001;60:1154-1163.
3. Uchino S, Fealy N, Baldwin I, Morimatsu H, Bellomo R: Continuous is not continuous: The incidence and impact of 'circuit down time' on uremic control during continuous veno-venous hemofiltration. Intens Care Med 2003;29:575-578.
4. Davenport A: Anticoagulation in patients with acute renal failure treated with continuous renal replacement therapies. Home Hemodial Int 1998;2:41-60.
5. Holt AW, Bierer P, Berstein AD, Bury LJ, Vedig AE: Continuous renal replacement therapy in critically ill patients: Monitoring circuit function. Anaesth Intens Care 1996;24:423-424.
6. Shulman RI, Singer M, Rock J: Keeping the circuit open: Lessons from the lab. Blood Purif 2002;20:275-281 .
7. Davenport A: Problems with anticoagulation; in Lameire N, Mehta R (eds): Complications of Dialysis: Recognition and Management. Boston, Marcel Dekker, 1999, pp 215-240.
8. Favre H, Martin Y, Stoermann C: Anticoagulation in continuous extracorporeal renal replacement therapy. Semin Dial 1996;9:112-118.
9. van der Wetering J, Westendorp RGJ, van der Hoeven JG, Stolk B, Feuth JDM, Chang PC: Heparin use in continuous renal replacement therapies: The struggle between filter coagulation and patient hemorrhage. J Am Soc Nephrol 1996;7:145-150.
10. Bellomo R, Teede H, Boyce N: Anticoagulant regimens in acute continuous hemodiafiltration: A comparative study. Intens Care Med 1993;19:329-332.
11. Davenport A: Heparin induced thrombocytopenia during renal replacement therapy. Hemodial Int 2004;in press.
12. Leitienne P, Fouque D, Rigal D, Adeleine P, Trzeciak MC, Laville M: Heparins and blood polymorphonuclear stimulation in hemodialysis: An expansion of the biocompatibility concept. Nephrol Dial Transplant 2000;15:1631-1637.
13. Wynckel A, Bernieh B, Toupance O, N'Guyen PH, Wong T, Lavaud S, Chanard J: Guidelines to the use of enoxparin in slow continuous dialysis. Contrib Nephrol. Basel, Karger, 1991, vol 93, pp 221-224.
14. Schepens D, De Keulenaer B: Efficacy and safety of nadropine as anticoagulant therapy in continuous venovenous hemofiltration. Blood Purif 2002;20:314.
15. Reeves JH, Gumming AR, Gallagher L, O'Brien JL, Santamaria JD: A controlled trial of low molecular weight heparin (dalteparin) versus unfractionated heparin as anticoagulant during continuous venovenous hemodialysis with filtration. Crit Care Med 1999;27:2224-2228.
16. Lindhoff-Last E, Betz C, Bauersachs R: Use of a low-molecular-weight heparinoid (danaparoid sodium) for continuous renal replacement therapy in intensive care patients. Clin Appl Thromb Hemost 2001;7:300-304.
17. Fischer KG: Hirudin in renal insufficiency. Semin Thromb Hemostat 2002;28:467-482.
18. Schneider T, Heuer B, Deller A, Boesken WH: Continuous haemofiltration with r-hirudin (lepirudin) as anticoagulant in a patient with heparin induced thrombocytopenia (HIT II). Wien Klin Wochenschr 2000;112:552-555.
19. Frank RD, Farber H, Lanzmich R, Floege J, Kierdorf HP: In vitro studies on hirudin elimination by haemofiltration: Comparison of three high flux membranes. Nephrol Dial Transplant 2002;17:1957-1963.
20. Hursting MJ, Alford KL, Becker JC, Brooks RL, Joffrion JL, Knappenberger GD, Kogan PW, Kogan TP, McKinney AA, Schwarz RP Jr: Novostatin (brand of argatroban): A small molecule, direct thrombin inhibitor. Semin Thromb Hemostat 1997;23:503-516.
21. Reddy BV, Nahlik L, Trevino S, Murray PT: Argatroban anticoagulation during renal replacement therapy. Blood Purif 2002;20:313-314.
22. Mehta RL, McDonald BR, Aguilar MM, Ward DM: Regional citrate anticoagulation for continuous arteriovenous hemodialysis in critically ill patients. Kid Int 1990;38:976-981.
23. Palsson R, Niles JR: Regional citrate anticoagulation in continuous venovenous hemofiltration in critically ill patients with a high risk of bleeding. Kid Int 1999;55:1991-1997.
24. Tolwani AJ, Campbell RC, Schenk MB, Allon M, Warnock DG: Simplified citrate anticoagulation for continuous renal replacement therapy. Kid Int 2001;60:370-374.
25. Kutsogiannis DJ, Mayers I, Chi WD, Gibney RT: Regional citrate anticoagulation in continuous venovenous hemodiafiltration. Am J Kid Dis 2000;35:802-811.
26. Bunchman T, Maxvold NJ, Barnett J, Hutchings A, Benfield MR: Pediatric hemofiltration: Normocarb dialysate solution with citrate anticoagulation. Pediatr Nephrol 2002;17:150-154.
27. Meier-Kriesche H-U, Gitomer J, Finkel K, DuBose T: Increased total to ionized calcium ratio during continuous venovenous hemodialysis with regional citrate anticoagulation. Crit Care Med 2001;29:748-752.
28. Zobel G, Ring E, Kuttnig M, Grubbauer HM: Continuous arteriovenous hemofiltration versus continuous venovenous hemofiltration in critically ill pediatric patients. Contrib Nephrol. Basel, Karger, 1991, vol 93, pp 257-260.29
29. Langenecker SA, Felfernig M, Werba A, Mueller CM, Chiari A, Zimpfer M: Anticoagulation with prostacyclin and heparin during continuous venovenous hemofiltration. Crit Care Med 1994;22:1774-1781.
30. Davenport A, Will EJ, Davison AM: Comparison of the use of standard heparin and prostacyclin anticoagulation in spontaneous and pump driven extracorporeal circuits in patients with combined acute renal and hepatic failure. Nephron 1994;66:431-4t37.
31. Akizawa T: Beneficial characteristics of protease inhibitor as an anticoagulant for extracorporeal circulation. Rinsho Ketsueki 1990;31:782-786.
32. Matsuo T, Kario K, Nakao K, Yamada T, Matsuo M: Anticoagulation with nafamostat mesilate, a synthetic protease inhibitor, in hemodialysis patients with a bleeding risk. Haemostatasis 1993;23:135-141.
33. Sperschneider H, Deppisch R, Beck W, Wolf H, Stein G: Impact of membrane choice and blood flow pattern on coagulation and heparin requirement potential consequences on lipid concentrations. Nephrol Dial Transplant 1997;12:2638-2646.
34. Davenport A: Pre vs. postdilution for continuous veno-venous hemofiltration? That is the question. Nephron Clin Pract. 2003;94:c83-c84.
35. Davenport A: Central Venous Catheters for Hemodialysis: How to overcome the problems. Home Hemodial Int 2000;2:43-45.